Skip to main content
Top
Published in: BMC Infectious Diseases 1/2022

Open Access 01-12-2022 | Hepatitis C | Research

Ten years countdown to hepatitis C elimination in Belgium: a mathematical modeling approach

Authors: Dana Busschots, Erwin Ho, Sarah Blach, Frederik Nevens, Homie Razavi, Brieuc Van Damme, Thomas Vanwolleghem, Geert Robaeys

Published in: BMC Infectious Diseases | Issue 1/2022

Login to get access

Abstract

Background

Chronic infection with the hepatitis C virus (HCV) remains a worldwide health problem. As a result, the World Health Organization (WHO) has set elimination targets by 2030. This study aims to examine the position of Belgium in meeting the WHO's targets by 2030.

Methods

A Markov disease progression model, constructed in Microsoft Excel, was utilized to quantify the size of the HCV-infected population, by the liver disease stages, from 2015 to 2030. Two scenarios were developed to (1) forecast the disease burden in Belgium under the 2019 Base and (2) see what is needed to achieve the WHO targets.

Results

It was estimated that the number of HCV RNA-positive individuals in Belgium in 2015 was 18,800. To achieve the WHO goals, Belgium needs to treat at least 1200 patients per year. This will only be feasible if the number of screening tests increases.

Conclusions

Belgium is on target to reach the WHO targets by 2030 but will have to make sustained efforts. However, eradicating HCV requires policy changes to significantly increase prevention, screening, and treatment, alongside public health promotion, to raise awareness among high-risk populations and health care providers.
Appendix
Available only for authorised users
Literature
1.
go back to reference WHO: Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection. In: World Health Organization; 2016: 138. WHO: Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection. In: World Health Organization; 2016: 138.
2.
go back to reference Litzroth A, Suin V, Wyndham-Thomas C, Quoilin S, Muyldermans G, Vanwolleghem T, Kabamba-Mukadi B, Verburgh V, Jacques M, Van Gucht S, et al. Low hepatitis C prevalence in Belgium: implications for treatment reimbursement and scale up. BMC Public Health. 2019;19(1):39.CrossRef Litzroth A, Suin V, Wyndham-Thomas C, Quoilin S, Muyldermans G, Vanwolleghem T, Kabamba-Mukadi B, Verburgh V, Jacques M, Van Gucht S, et al. Low hepatitis C prevalence in Belgium: implications for treatment reimbursement and scale up. BMC Public Health. 2019;19(1):39.CrossRef
3.
go back to reference Busschots D, Toghanian S, Bielen R, Salomonsson S, Koc OM, Hendrickx G, Jadoul M, Nevens F, Sokal E, Brixko C, et al. Eliminating viral hepatitis C in Belgium: the micro-elimination approach. BMC Infect Dis. 2020;20(1):181.CrossRef Busschots D, Toghanian S, Bielen R, Salomonsson S, Koc OM, Hendrickx G, Jadoul M, Nevens F, Sokal E, Brixko C, et al. Eliminating viral hepatitis C in Belgium: the micro-elimination approach. BMC Infect Dis. 2020;20(1):181.CrossRef
4.
go back to reference Pawlotsky J-M, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, Marra F, Puoti M, Wedemeyer H. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69(2):461–511.CrossRef Pawlotsky J-M, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, Marra F, Puoti M, Wedemeyer H. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69(2):461–511.CrossRef
5.
go back to reference Vandijck D, Moreno C, Stärkel P, Van Damme P, Van Vlierberghe H, Hindman S, Razavi H, Laleman W. Current and future health and economic impact of hepatitis C in Belgium. Acta Gastro-Enterol Belg. 2014;77:285–90. Vandijck D, Moreno C, Stärkel P, Van Damme P, Van Vlierberghe H, Hindman S, Razavi H, Laleman W. Current and future health and economic impact of hepatitis C in Belgium. Acta Gastro-Enterol Belg. 2014;77:285–90.
6.
go back to reference Federale Overheidsdienst Volksgezondheid VvdveL: Belgisch staatsblad-Moniteur Belge: Protocolakkoord 'HCV-plan'. In. Brussels; 08.08.2014: 57926–57940. Federale Overheidsdienst Volksgezondheid VvdveL: Belgisch staatsblad-Moniteur Belge: Protocolakkoord 'HCV-plan'. In. Brussels; 08.08.2014: 57926–57940.
8.
go back to reference Busschots D, Kremer C, Koc Ö, Heyens L, Bielen R, Apers L, Florence E, Messiaen P, Van Laethem K, Van Wijngaerden E, et al. The hepatitis C cascade of care in the Belgian HIV population: one step closer to elimination. Int J Infect Dis. 2021;105:217–23.CrossRef Busschots D, Kremer C, Koc Ö, Heyens L, Bielen R, Apers L, Florence E, Messiaen P, Van Laethem K, Van Wijngaerden E, et al. The hepatitis C cascade of care in the Belgian HIV population: one step closer to elimination. Int J Infect Dis. 2021;105:217–23.CrossRef
9.
go back to reference Busschots D, Kremer C, Bielen R, Koc Ö, Heyens L, Dercon E, Verrando R, Windelinckx T, Maertens G, Bourgeois S, et al. Identification and treatment of viral hepatitis C in persons who use drugs: a prospective, multicenter outreach study in Flanders, Belgium. Harm Reduct J. 2021;18(1):54.CrossRef Busschots D, Kremer C, Bielen R, Koc Ö, Heyens L, Dercon E, Verrando R, Windelinckx T, Maertens G, Bourgeois S, et al. Identification and treatment of viral hepatitis C in persons who use drugs: a prospective, multicenter outreach study in Flanders, Belgium. Harm Reduct J. 2021;18(1):54.CrossRef
10.
go back to reference Busschots D, Kremer C, Bielen R, Koc OM, Heyens L, Brixko C, Laukens P, Orlent H, Bilaey P, De Smet F, et al. A multicentre interventional study to assess blood-borne viral infections in Belgian prisons. BMC Infect Dis. 2021;21(1):708.CrossRef Busschots D, Kremer C, Bielen R, Koc OM, Heyens L, Brixko C, Laukens P, Orlent H, Bilaey P, De Smet F, et al. A multicentre interventional study to assess blood-borne viral infections in Belgian prisons. BMC Infect Dis. 2021;21(1):708.CrossRef
11.
go back to reference Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161–76.CrossRef Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161–76.CrossRef
12.
go back to reference European Union HCV Collaborators. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(5):325–36.CrossRef European Union HCV Collaborators. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(5):325–36.CrossRef
13.
go back to reference Sasse A, Deblonde J, De Rouck M, Montourcy M, Van Beckhoven D: Epidemiologie van AIDS en HIV-infectie in België. In. Brussels: Wetenschappelijk Instituut Volksgezondheid; 2018. Sasse A, Deblonde J, De Rouck M, Montourcy M, Van Beckhoven D: Epidemiologie van AIDS en HIV-infectie in België. In. Brussels: Wetenschappelijk Instituut Volksgezondheid; 2018.
15.
go back to reference Mathei C, Bourgeois S, Blach S, Brixko C, Mulkay JP, Razavi H, Robaeys G. Mitigating the burden of hepatitis C virus among people who inject drugs in Belgium. Acta Gastroenterol Belg. 2016;79(2):227–32.PubMed Mathei C, Bourgeois S, Blach S, Brixko C, Mulkay JP, Razavi H, Robaeys G. Mitigating the burden of hepatitis C virus among people who inject drugs in Belgium. Acta Gastroenterol Belg. 2016;79(2):227–32.PubMed
18.
go back to reference Bourgeois S, Blach S, Blach C, Laleman W, Matheï C, Mulkay JP, Ravazi H, Robaeys G, Stärkel P, Van Damme P, et al. Achieving WHO recommendations for hepatitis C virus elimination in Belgium. Acta Gastroenterol Belg. 2016;79(2):222–6.PubMed Bourgeois S, Blach S, Blach C, Laleman W, Matheï C, Mulkay JP, Ravazi H, Robaeys G, Stärkel P, Van Damme P, et al. Achieving WHO recommendations for hepatitis C virus elimination in Belgium. Acta Gastroenterol Belg. 2016;79(2):222–6.PubMed
19.
go back to reference Gerkens S, Martin N, Thiry N, Hulstaert F: Hepatitis C: Screening en Preventie. In. Brussel: Federaal Kenniscentrum voor de Gezondheiszorg (KCE); 2011. Gerkens S, Martin N, Thiry N, Hulstaert F: Hepatitis C: Screening en Preventie. In. Brussel: Federaal Kenniscentrum voor de Gezondheiszorg (KCE); 2011.
20.
go back to reference EASL. EASL recommendations on treatment of hepatitis C: final update of the series. J Hepatol. 2020;73:1170–218.CrossRef EASL. EASL recommendations on treatment of hepatitis C: final update of the series. J Hepatol. 2020;73:1170–218.CrossRef
22.
go back to reference Beutels M, Van Damme P, Aelvoet W, Desmyter J, Dondeyne F, Goilav C, et al. Prevalence of hepatitis A, B and C in the Flemish population. Eur J Epidemiol. 1997;13(3):275–80.CrossRef Beutels M, Van Damme P, Aelvoet W, Desmyter J, Dondeyne F, Goilav C, et al. Prevalence of hepatitis A, B and C in the Flemish population. Eur J Epidemiol. 1997;13(3):275–80.CrossRef
23.
go back to reference De Maeght S, Henrion J, Bourgeois N, de Galocsy C, Langlet P, Michielsen P, et al. A pilot observational survey of hepatitis C in Belgium. Acta Gastroenterol Belg. 2008;71(1):4–8.PubMed De Maeght S, Henrion J, Bourgeois N, de Galocsy C, Langlet P, Michielsen P, et al. A pilot observational survey of hepatitis C in Belgium. Acta Gastroenterol Belg. 2008;71(1):4–8.PubMed
24.
go back to reference Engstrom A, Adamsson C, Allebeck P, Rydberg U. Mortality in patients with substance abuse: a follow-up in Stockholm County, 1973–1984. Int J Addict. 1991;26(1):91–106.CrossRef Engstrom A, Adamsson C, Allebeck P, Rydberg U. Mortality in patients with substance abuse: a follow-up in Stockholm County, 1973–1984. Int J Addict. 1991;26(1):91–106.CrossRef
25.
go back to reference Frischer M, Goldberg D, Rahman M, Berney L. Mortality and survival among a cohort of drug injectors in Glasgow, 1982–1994. Addiction. 1997;92(4):419–27.CrossRef Frischer M, Goldberg D, Rahman M, Berney L. Mortality and survival among a cohort of drug injectors in Glasgow, 1982–1994. Addiction. 1997;92(4):419–27.CrossRef
26.
go back to reference Hickman M, Carnwath Z, Madden P, Farrell M, Rooney C, Ashcroft R, et al. Drug-related mortality and fatal overdose risk: pilot cohort study of heroin users recruited from specialist drug treatment sites in London. J Urban Health. 2003;80(2):274–87.CrossRef Hickman M, Carnwath Z, Madden P, Farrell M, Rooney C, Ashcroft R, et al. Drug-related mortality and fatal overdose risk: pilot cohort study of heroin users recruited from specialist drug treatment sites in London. J Urban Health. 2003;80(2):274–87.CrossRef
27.
go back to reference Oppenheimer E, Tobutt C, Taylor C, Andrew T. Death and survival in a cohort of heroin addicts from London clinics: a 22-year follow-up study. Addiction. 1994;89(10):1299–308.CrossRef Oppenheimer E, Tobutt C, Taylor C, Andrew T. Death and survival in a cohort of heroin addicts from London clinics: a 22-year follow-up study. Addiction. 1994;89(10):1299–308.CrossRef
28.
go back to reference Perucci CA, Davoli M, Rapiti E, Abeni DD, Forastiere F. Mortality of intravenous drug users in Rome: a cohort study. Am J Public Health. 1991;81(10):1307–10.CrossRef Perucci CA, Davoli M, Rapiti E, Abeni DD, Forastiere F. Mortality of intravenous drug users in Rome: a cohort study. Am J Public Health. 1991;81(10):1307–10.CrossRef
29.
go back to reference Bjornaas MA, Bekken AS, Ojlert A, Haldorsen T, Jacobsen D, Rostrup M, et al. A 20-year prospective study of mortality and causes of death among hospitalized opioid addicts in Oslo. BMC Psychiatry. 2008;8:8.CrossRef Bjornaas MA, Bekken AS, Ojlert A, Haldorsen T, Jacobsen D, Rostrup M, et al. A 20-year prospective study of mortality and causes of death among hospitalized opioid addicts in Oslo. BMC Psychiatry. 2008;8:8.CrossRef
30.
go back to reference Kamper-Jorgensen M, Ahlgren M, Rostgaard K, Melbye M, Edgren G, Nyren O, et al. Survival after blood transfusion. Transfusion. 2008;48(12):2577–84.CrossRef Kamper-Jorgensen M, Ahlgren M, Rostgaard K, Melbye M, Edgren G, Nyren O, et al. Survival after blood transfusion. Transfusion. 2008;48(12):2577–84.CrossRef
31.
go back to reference Blach S, Kondili LA, Aghemo A, Cai Z, Dugan E, Estes C, Gamkrelidze I, Ma S, Pawlotsky JM, Razavi-Shearer D, et al. Impact of COVID-19 on global HCV elimination efforts. J Hepatol. 2021;74(1):31–6.CrossRef Blach S, Kondili LA, Aghemo A, Cai Z, Dugan E, Estes C, Gamkrelidze I, Ma S, Pawlotsky JM, Razavi-Shearer D, et al. Impact of COVID-19 on global HCV elimination efforts. J Hepatol. 2021;74(1):31–6.CrossRef
32.
go back to reference Bielen R, Koc OM, Busschots D, Robaeys G, Aertgeerts B, Vaes B, Mamouris P, Mathei C, Goderis G, Nevens F. Assessing testing rates for viral hepatitis B and C by general practitioners in Flanders, Belgium: a registry-based study. BMJ Open. 2019;9(5): e026464.CrossRef Bielen R, Koc OM, Busschots D, Robaeys G, Aertgeerts B, Vaes B, Mamouris P, Mathei C, Goderis G, Nevens F. Assessing testing rates for viral hepatitis B and C by general practitioners in Flanders, Belgium: a registry-based study. BMJ Open. 2019;9(5): e026464.CrossRef
33.
go back to reference Gerkens S, Martin N, Thiry N, Hulstaert F. Hepatitis C: screening en preventie. Health Technology Assessment (HTA). In., vol. Reports 173A.: KCE; 2014. Gerkens S, Martin N, Thiry N, Hulstaert F. Hepatitis C: screening en preventie. Health Technology Assessment (HTA). In., vol. Reports 173A.: KCE; 2014.
34.
go back to reference Ocal S, Muir AJ. Addressing Hepatitis C in the American incarcerated population: strategies for nationwide elimination. Curr HIV/AIDS Rep. 2020;17(1):18–25.CrossRef Ocal S, Muir AJ. Addressing Hepatitis C in the American incarcerated population: strategies for nationwide elimination. Curr HIV/AIDS Rep. 2020;17(1):18–25.CrossRef
35.
go back to reference Hoffmann P. Prevention and control of viral hepatitis in IDU/prisoners in Luxembourg. In: VHPB Meeting Brussels: 2017; 2017. Hoffmann P. Prevention and control of viral hepatitis in IDU/prisoners in Luxembourg. In: VHPB Meeting Brussels: 2017; 2017.
Metadata
Title
Ten years countdown to hepatitis C elimination in Belgium: a mathematical modeling approach
Authors
Dana Busschots
Erwin Ho
Sarah Blach
Frederik Nevens
Homie Razavi
Brieuc Van Damme
Thomas Vanwolleghem
Geert Robaeys
Publication date
01-12-2022
Publisher
BioMed Central
Keyword
Hepatitis C
Published in
BMC Infectious Diseases / Issue 1/2022
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-022-07378-3

Other articles of this Issue 1/2022

BMC Infectious Diseases 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.